CAPRICOR THERAPEUTICS INC. - COMMON STOCK

Capricor Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

07 8 2024 15:05:01 提供 Nasdaq GlobeNewswire

Capricor Therapeutics to Present Second Quarter 2024 Financial Results and Recent Corporate Update on August 7

31 7 2024 08:00:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

01 7 2024 08:00:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (CAP-1002) in Both Skeletal Muscle and Cardiac Function in the HOPE-2 OLE Study in Duchenne Muscular Dystrophy

28 6 2024 08:00:00 提供 Nasdaq GlobeNewswire

CORRECTION: Capricor Therapeutics

25 6 2024 09:30:57 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy

25 6 2024 07:30:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway

11 6 2024 08:25:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy

04 6 2024 08:00:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

13 5 2024 15:05:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

09 5 2024 08:15:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics to Present at Upcoming Scientific and Medical Conferences

08 5 2024 08:00:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics to Present First Quarter 2024 Financial Results and Recent Corporate Update on May 13

06 5 2024 08:00:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy

24 4 2024 08:00:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics to Present at Upcoming Investor Conferences

21 3 2024 07:30:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

06 3 2024 07:30:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

29 2 2024 15:05:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy

27 2 2024 07:30:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29

22 2 2024 07:30:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward Commercialization

20 2 2024 07:30:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2

24 1 2024 08:15:00 提供 Nasdaq GlobeNewswire